- Home
- LCTX vs BRKH Comparison
LCTX vs BRKH Comparison
Compare LCTX & BRKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- BRKH
- Stock Information
- Founded
- LCTX 1990
- BRKH 2021
- Country
- LCTX United States
- BRKH United States
- Employees
- LCTX 75
- BRKH N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- BRKH Blank Checks
- Sector
- LCTX Health Care
- BRKH Finance
- Exchange
- LCTX Nasdaq
- BRKH Nasdaq
- Market Cap
- LCTX 171.8M
- BRKH 170.6M
- IPO Year
- LCTX N/A
- BRKH 2021
- Fundamental
- Price
- LCTX $0.94
- BRKH $11.25
- Analyst Decision
- LCTX Strong Buy
- BRKH
- Analyst Count
- LCTX 3
- BRKH 0
- Target Price
- LCTX $5.67
- BRKH N/A
- AVG Volume (30 Days)
- LCTX 290.8K
- BRKH 31.6K
- Earning Date
- LCTX 11-07-2024
- BRKH 01-01-0001
- Dividend Yield
- LCTX N/A
- BRKH N/A
- EPS Growth
- LCTX N/A
- BRKH N/A
- EPS
- LCTX N/A
- BRKH N/A
- Revenue
- LCTX $6,186,000.00
- BRKH N/A
- Revenue This Year
- LCTX N/A
- BRKH N/A
- Revenue Next Year
- LCTX $119.00
- BRKH N/A
- P/E Ratio
- LCTX N/A
- BRKH N/A
- Revenue Growth
- LCTX N/A
- BRKH N/A
- 52 Week Low
- LCTX $0.77
- BRKH $10.48
- 52 Week High
- LCTX $1.61
- BRKH $11.28
- Technical
- Relative Strength Index (RSI)
- LCTX 51.44
- BRKH 59.43
- Support Level
- LCTX $0.87
- BRKH $11.12
- Resistance Level
- LCTX $0.94
- BRKH $11.27
- Average True Range (ATR)
- LCTX 0.04
- BRKH 0.00
- MACD
- LCTX 0.00
- BRKH -0.00
- Stochastic Oscillator
- LCTX 72.82
- BRKH 48.39
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About BRKH BurTech Acquisition Corp.
BurTech Acquisition Corp is a blank check company.